NEP-2T
Dual GIP/GLP-1 Receptor Agonist
Molecular Details
Overview
NEP-2T is a synthetic 39-amino-acid peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. A C20 fatty-diacid moiety promotes albumin binding and extends its plasma half-life to approximately five days, supporting once-weekly administration in research protocols. Dual GIP/GLP-1 agonism is an active area of metabolic research, studied for its combined effects on insulin secretion, glucose homeostasis, appetite signaling, and body-weight regulation.
Published Research
SURPASS Phase 3 — Glycemic Outcomes
Phase 3 clinical trial · 2022Published clinical research on tirzepatide, a dual GIP/GLP-1 receptor agonist, in the SURPASS Phase 3 program reported dose-dependent HbA1c reductions (approximately 2.3% at the 15 mg dose) alongside body-weight reductions in participants with type 2 diabetes.
SURMOUNT-1 — Body Composition
Phase 3 clinical trial · 2022In the SURMOUNT-1 trial (Jastreboff et al., 2022), tirzepatide was studied in adults with obesity without type 2 diabetes; the 15 mg cohort showed a mean body-weight reduction of approximately 20.9% at 72 weeks.
Dual-Agonist Receptor Pharmacology
In vitro (cell-based) · 2021Receptor-binding and cell-based insulin-secretion assays have characterized dual GIP and GLP-1 receptor agonism, establishing the mechanistic basis for combined incretin-receptor activation.
Half-Life Extension via Fatty-Diacid Modification
Preclinical / Review · 2023The C20 fatty-diacid moiety and its role in albumin binding and extended plasma half-life have been characterized in the medicinal-chemistry literature, supporting once-weekly administration schedules in research.
Storage & Handling
Store lyophilized powder at –20°C or –80°C for long-term storage. Reconstitute with bacteriostatic or sterile water and keep the reconstituted solution refrigerated at 2–8°C. Protect from light and moisture; avoid repeated freeze-thaw cycles.
For research purposes only. Not intended for human consumption. This profile summarizes published preclinical literature and does not constitute medical, clinical, or dosage guidance.